Compare · TLC vs TLGT
TLC vs TLGT
Side-by-side comparison of Taiwan Liposome Company, Ltd. (TLC) and Teligent, Inc. (TLGT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TLC and TLGT operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- TLC is the larger of the two at $292.2M, about 18.1x TLGT ($16.1M).
- TLC has more recent analyst coverage (2 ratings vs 0 for TLGT).
- Company
- Taiwan Liposome Company, Ltd.
- Teligent, Inc.
- Price
- $6.94+0.00%
- $0.17-13.18%
- Market cap
- $292.2M
- $16.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 2
- 0
Taiwan Liposome Company, Ltd.
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). The BioSeizer lipid formulation technology is designed to enable local sustained release and fast onset of APIs at the site of disease or injury with enhanced pharmacokinetic (PK) control by customization of lipid layers; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site. Its lead product candidate is TLC599, an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP), which is in Phase III clinical trial for the treatment of knee osteoarthritis pain. The company's product candidates also comprise TLC590, a non-opioid BioSeizer formulation of the API ropivacaine that has completed Phase II clinical trial to treat post-surgical pain; TLC399, a multilamellar and multivesicular BioSeizer formulation of DSP, which is in Phase II clinical trial for ophthalmology indications; TLC178, an API that is in Phase I/II dose escalation trial to treat rhabdomyosarcoma; and TLC19 that is in Phase I clinical trial to treat COVID-19.Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei, Taiwan.
Teligent, Inc.
Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The company's topical semi-solid and liquid products are used in various applications that range from cosmetics and cosmeceuticals; and the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. It sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was incorporated in 1977 and is based in Buena, New Jersey.
Latest TLC
- TLC Announces TLC599 Agreement with Endo
- TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy
- SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)
- SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)
- SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)
- SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)
- SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)
- SEC Form 6-K filed by Taiwan Liposome Company, Ltd.
- SEC Form 25 filed by Taiwan Liposome Company, Ltd.
- SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)
Latest TLGT
- SEC Form 25-NSE filed by Teligent, Inc.
- Teligent, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Teligent to Pursue Asset Sale through Voluntary Chapter 11 Process
- SEC Form 3 filed by new insider Benesch Joseph
- SEC Form 3 filed by new insider Lozynski Alyssa
- Teligent, Inc. filed SEC Form 8-K: Leadership Update
- Teligent, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form 10-Q filed by Teligent, Inc.
- Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update
- Teligent, Inc. to Hold Conference Call for Second Quarter 2021 Financial Results on Monday, August 16, 2021